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Abstract
Background Mutations in the RPGR gene predominantly
cause rod photoreceptor disorders with a large variability in
clinical course. In this report, we describe two families with
mutations in this gene and cone involvement.
Methods We investigated an X-linked cone dystrophy
family (1) with 25 affected males, 25 female carriers, and
21 non-carriers, as well as a small family (2) with one
affected and one unaffected male. The RPGR gene was
analyzed by direct sequencing. All medical records were
evaluated, and all available data on visual acuity, color
vision testing, ophthalmoscopy, fundus photography, fundus
autofluorescence, Goldmann perimetry, SD-OCT, dark
adaptation, and full-field electroretinography (ERG) were
registered. Cumulative risks of visual loss were studied
with Kaplan–Meier product-limit survival analysis.
Results Both families had a frameshift mutation in ORF15
of the RPGR gene; family 1 had p.Ser1107ValfsX4, and
family 2 had p.His1100GlnfsX10. Mean follow up was
13 years (SD 10). Virtually all affected males showed
reduced photopic and normal scotopic responses on ERG.
Fifty percent of the patients had a visual acuity of <0.5 at
age 35 years (SE 2.2), and 75% of the patients was legally
blind at age 60 years (SE 2.3). Female carriers showed no
signs of ocular involvement.
Conclusions This report describes the clinical course and
visual prognosis in two families with cone dystrophy due to
RPGR mutations in the 3’ terminal region of ORF15.
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Introduction
Cone dystrophy (CD) is a progressive disease in which
the cone photoreceptors are primarily affected. Patients
experience increasing photophobia, and develop loss of
visual acuity, color vision disturbances, and central
visual field defects. An important clinical hallmark for
diagnosis is reduction of cone responses with preserva-
tion of rod responses on full-field electroretinogram
(ERG) [1, 2]. All three inheritance patterns occur in CD;
15% is autosomal dominant, 80% autosomal recessive,
and 5% X-linked. Revelation of the genetic background
and genotype-phenotype correlation in CD is currently
ongoing, improving clinical counseling and prediction of
visual decline.
A common cause of X-linked retinitis pigmentosa (RP)
are mutations in the retinitis pigmentosa GTPase regulator
gene (RPGR; Xp21.1) [3–8] The gene has also been
reported in X-linked cone-rod dystrophy (CRD) [9–13]o r
even in pure CD [3, 14, 15]. Although the clinical course of
patients with RPGR mutations and RP has been evaluated
[16], how the disease progresses in CD patients is currently
unknown.
In this report, we present two families with CD due to
mutations at the 3’ terminal end of ORF15. We carefully
studied the course of disease in 26 affected males and 25
female carriers during a long period of follow-up, and
established a model for visual outcome that can be used for
clinical counseling.
Patients and methods
Study population
We studied a pedigree of 71 relatives (25 affected males; 25
female carriers; 21 non-carriers) of one Dutch family
(family 1), as well as one affected male and one unaffected
sibling of the second family (family 2) (Fig. 1). All affected
males of family 1 had been diagnosed with CD. We were
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Fig. 1 a Pedigree of family 1 with X-linked cone dystrophy (CD)
showing segregation of the c.3317dup (p.Ser1107ValfsX4) mutation in
ORF15 of the RPGR gene. b Pedigree of family 2 with CD showing
segregation of the c.3300_3301del (p.His1100GlnfsX10) mutation in
ORF15 of the RPGR gene. Open square and circle, unaffected males
and females; black square, affected males; open circle with a dot,a n
obligate female carrier; dashed symbols denote deceased individuals
1528 Graefes Arch Clin Exp Ophthalmol (2011) 249:1527–1535not able to contact five patients and 11 female carriers.
All other patients were ascertained at three medical
centers in the Netherlands: the Netherlands Institute for
Neuroscience (NIN), Erasmus Medical Center Rotterdam,
and the St. Oosterschelde Hospital in Goes. The study
was approved by the Medical Ethics Committee of
Erasmus Medical Center and adhered to the tenets of
the Declaration of Helsinki. All participants provided
signed, informed consent for participation in the study,
retrieval of medical records, and use of blood and DNA
for research.
Clinical examination
Medical charts were retrieved from the patients’ ophthal-
mologists, and all available data on Snellen visual acuity,
color vision (Hardy-Rand-Rittler color-vision test, Ishihara
pseudoisochromatic plates, or Farnsworth Panel D15/
D 2 8t e s t ) ,G o l d m a n np e r i m e t ry, slit-lamp and fundus
examination, and ERGs were recorded. Patients with
incomplete or no available data from the previous 5 years
were invited for a work-up examination at one of the
clinics. All patients underwent a full-field ERG with
contact lens electrodes, following the recommendations of
the International Society for Clinical Electrophysiology of
Vision (ISCEV) [17]. Subsequently, we performed a
Goldmann Weeker’s dark adaptometry (DA), spectral
domain-ocular coherence tomography (SD-OCT), fundus
photography, and fundus autofluorescence (FAF) in a
subset of carriers and patients.
Molecular genetic analysis
Blood samples were obtained from all participating family
members of family 1 (n=87), and family 2 (n=3). DNAwas
isolated from peripheral blood lymphocytes by standard
procedures. Molecular analyses were carried out as
described [18]. In short, the coding region and intron/exon
Fig. 2 a Sequence chromatograms of the RPGR ORF15 gene for
family 1 with the c.3317dup (p.Ser1107ValfsX4) mutation. The
top chromatogram shows a hemizygous mutated allele (duplication
of an adenine nucleotide in the A base stretch); the middle
chromatogram a heterozygous mutated sequence in a female carrier;
the bottom chromatogram shows the normal allele. b Sequence
chromatograms of the RPGR O R F 1 5g e n ef o rf a m i l y2w i t ht h e
c.3300_3301del (p.His1100GlnfsX10) mutation. The top chromatogram
shows the hemizygous deleted allele; the middle chromatogram shows
the heterozygous mutated allele in a female carrier; the bottom
chromatogram the normal allele. The displayed chromatograms in a
and b are reverse sequences causing the typical disturbed sequence
patterns in such a heterozygous carrier chromatogram to the left
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Fig. 3 a Composite fundus photograph of the left eye of patient V-4, of
family 1 with a c.3317dup (p.Ser1107ValfsX4) mutation in the RPGR
ORF15 gene, performed at age 27 years. No macular abnormalities are
apparent yet. b Composite fundus photograph of the left eye of patient
IV-19 of family 1 with the c.3317dup (p.Ser1107ValfsX4) mutation in
RPGR ORF15, performed at age 71 years. The retina shows retinal
pigment epithelium atrophy in the macular region and peripapillary
atrophy. The patient has high myopia
Fig. 4 Fundus photographs, fundus autofluorescence images (FAF),
spectral domain-OCTs (SD-OCT), full-field electroretinograms (ERG),
and Goldman-Weekers dark adaptation curves (DA) of the left eye of
patient V-7, performed at age 50, and carrier VI-6, performed at age
24, both of family 1. The ERGs were performed according to the
standard International Society for Clinical Electrophysiology of Vision
(ISCEV) protocol. Best-corrected visual acuity of the patient and
carrier was 0.10 and 1.0, respectively. a Fundus photograph of patient
V-7, showing peripapillary atrophy and pigment clumping with
atrophic lesions in the macula. The patient has high myopia (S-9.0
D). The arrow denotes the position of the SD-OCT. The OCT signifies
thinning of the fovea (158 μm), pigment clumping, and atrophy of the
RPE. The FAF shows a high-density autofluorescent peri-macular ring.
The ERG of this patient is shown at the left with traces of an age-related
control person at right for purposes of comparison. Replications of the
responses are shown as thin traces, the average as solid. Note the
significantly reduced cone-specific responses with preserved rod
responses. b Fundus photograph of carrier VI-4, showing a normal
optic nerve and macula. The arrow denotes the position of the SD-OCT
image. The OCT denotes a slightly reduced foveal thickness (232 μm),
but an otherwise intact photoreceptor and RPE cell layer. FAF shows no
abnormalities. The ERG is shown at the left with normal control traces
at right. Replications of the responses are shown as thin traces, the
average as solid. No abnormalities were present. c The DA-curves of
patient V-7 (diamonds), carrier VI-4 (squares) and a normal control
person (grey dots) with time (min) on the X-axis and threshold (dB) on
the Y-axis. The cone plateau for the patient is elevated by ~1 log-unit.
The S2 phase, i.e., the straight lines in the initial rod adaptation phase,
has the same slope as the normal control although the level is 1 log-unit
apart. The latter can be explained by the difficulty of the patient to
observe the fixation mark due to his low vision. The threshold for the
ERG response in the extended ISCEV ERG protocol was not elevated.
The DA for the carrier did not differ from normal
b
1530 Graefes Arch Clin Exp Ophthalmol (2011) 249:1527–1535boundaries of the RPGR ORF15 region were amplified by
polymerase chain reaction (PCR) using M13 tail sequences
at the 5’ ends of the target-specific primers. Sanger
sequencing reactions were performed using these M13 tail
sequences. Primer sequences and reaction conditions are
available upon request.
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Proportions of categorical variables between two groups
were compared using the Chi-square test. Cumulative risks
of visual loss were studied with Kaplan–Meier product-
limit survival analysis, with low vision (visual acuity<0.5)
or legal blindness (visual acuity ≤0.1) as outcomes.
Participants older than 60 were pooled to maintain unbiased
estimates.
Results
Mutation analysis
Pedigrees of both families are provided in Fig. 1.I n2 5
affected males and in 25 female carriers of family 1, the
1-bp insertion c.3317dup (p.Ser1107ValfsX4) in RPGR
ORF15 (NM_001034853.1) was detected as the causative
mutation (Fig. 2a). This earlier described frameshift
mutation [11] is located at the C-terminus of the ORF15
protein and results in premature truncation of the protein.
Full co-segregation of the mutation and the disease was
observed in the pedigree; no mutation was detected in 10
unaffected males and 11 unaffected females.
In the proband of family 2, a novel 2-bp deletion
c.3300_3301del (p.His1100GlnfsX10) in RPGR ORF15
was identified (Fig. 2b). This mutation also resulted in a
frameshift mutation, leading to a premature truncation of
the protein at amino acid 1110 of the C-terminus. This
mutation was also present in his unaffected daughter, and
was not identified in his unaffected brother.
Clinical findings and risk of visual decline
For family 1, the clinical findings of all affected males (n=
25), female carriers (n=25), and non-carriers (n=21) are
summarized in Table 1. Data on multiple visits were
available with a mean follow-up of 13 years (SD 10). The
mean age at onset was 36.2 (SD 3.1) years, and all patients
showed progression of the disease. Hemeralopia was a first
symptom in 8/25 (32%), preceding visual loss. Nystagmus
was not observed in any patient. High myopia, refractive
error of −6 D or worse, was common (19/25, 76%) in male
patients, significantly more common than in female carriers
(2/25, 8%; p<0.001). High myopia was not present in non-
carriers. All three color axes were severely disturbed in all
patients, except in one. This patient was relatively young
(21 years), had normal visual acuity, only mild color vision
disturbances, and a normal macula.
Macular appearance deteriorated progressively in most
patients, and ranged from no abnormalities to a Bull’s eye
maculopathy or atrophy (Fig. 3). Goldmann perimetry was
abnormal in all patients, and showed a reduced central
sensitivity (n=3) or a (relative) central scotoma (n=22).
ERG demonstrated reduced or absent photopic responses
with normal scotopic responses in 24/25 patients. In these
patients, the latter remained normal during follow-up. In the
remaining patient (age 72 years), the ERG did show slightly
reduced rod responses, however, this occurred only after
22 years of disease duration. All carriers (and non-carriers)
had a normal visual acuity, normal macular appearance, and
normal ERG. Figure 4 illustrates the clinical findings of
patient V-7 and carrier VI-4 of family 1, and shows a fundus
photograph, FAF, SD-OCT, ERG, and DA-curve.
Figure 5 shows the cumulative risk of visual decline as a
function of age in all affected males of family 1. Low vision
was present in 50% of patients at age 35 years (SE 2.2); and
in 75% of patients at 40 years (SE 1.1). Legal blindness
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Fig. 5 a Kaplan–Meier survival curves showing the cumulative
incidence of low vision (visual acuity <0.50) as a function of age. b
Kaplan–Meier survival curves showing the cumulative incidence of
legal blindness (visual acuity ≤0.10) as a function of age
1532 Graefes Arch Clin Exp Ophthalmol (2011) 249:1527–1535was present in 50% at 47 years (SE 3.4), and in 75% at
60 years (SE 2.3).
With respect to family 2, the proband developed color
vision disturbances at age 16 years, and a progressively
deteriorating visual acuity since age 43 years to counting
fingers at age 75 years. He had high myopia, severely
disturbed color vision in all three axes, and atrophic lesions
in the macula. Goldmann perimetry showed a central
scotoma with a normal periphery, and ERG revealed
absent photopic responses with normal rod responses. His
brother had a normal visual acuity with no color vision
disturbances and a normal macular appearance.
Discussion
In this report, we describe two families with RPGR
mutations in the 3’ terminal end of ORF15 and cone
pathology.Theonsetinthesefamilies wasrelativelylate,i.e.,
third and fourth decades, and visual acuity declined to legal
blindness within two decades thereafter. The onset and
clinical course were rather homogeneous in all affected
individuals. It was remarkable that rod function remained
unaffected in almost all patients. Only in one patient with a
long duration of disease, rod responses were slightly
diminished. This coincided with a normal peripheral visual
field and no nyctalopia, indicating that the rod decay in this
person was not clinically significant.
The RPGR gene is known to express different isoforms
caused by alternative splicing [3]. Two of these protein
isoforms are localized in the connecting cilium of cone and
rod photoreceptors. The first is encoded by the most
commonly expressed transcript, RPGR-ORF15, containing
exons 1 through ORF15 (a large exon consisting of exon 15
extending into a part of intron 15). The other, RPGR-ex1-
19, contains exons 1 through 19 but lacks exons 14 and 15
[3]. Exons 1–14 contain six RCC1-like domains; their main
function is to facilitate interaction with other proteins [19–
22]. Mutations within these domains lead to reduced or
abolished protein interactions [19]. The ORF15 region
encodes for a repetitive glycine and glutamic acid rich
protein domain of unknown function [3, 4]. It has been
demonstrated in the mouse that reduction of this repetitive
region can preserve a normal protein function [21]. Most
reported mutations in the first 14 exons are nonsense or
frameshift mutations which can lead to nonsense-mediated
decay of the mRNA (NMD), and low or absent levels of the
transcript. In contrast, nonsense or frameshift mutations in
ORF15 are less likely to lead to NMD since this is the last
exon of the transcript [23], and a series of truncated
proteins of varying length can be found [7].
Until now,300pathogenicmutations havebeendiscovered
in the RPGR gene. Most lead to RP (n=287), only seven
mutations have been associated with CRD (Fig. 6)[ 24].
Systemic involvement like respiratory tract infections or
hearing loss has been described in only a few patients [25].
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Fig. 6 LocalizationofallknownmutationsintheRPGR ORF15 isoform
(n=300) stratified per phenotype and per exon. *: Retinitis pigmentosa;
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dystrophy; n=7. $: Cone dystrophy; n=4. #: Retinitis pigmentosa with
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three earlier publications reported a phenotype of pure CD
[3, 14, 15]. More than half (164/287; 57%) of the mutations
leading to RP occur in the ORF15 region; and all mutations
that cause CRD and CD have been found at this site. No
mutations have been detected in exon 16–19 (Fig. 6).
Literature on the clinical course in CD patients with
mutations in RPGR is lacking. In this report, we describe
the onset and course of visual acuity in 25 patients of a
family with a known duplication (c.3317dup), and in a
proband with a newly identified deletion (c.3300_3301del)
in ORF15. Both are frameshift mutations located in the
terminal 3’ region of this exon, causing premature
termination of the protein. Both mutations resulted in a
loss of only ~40-50 amino acids at the C-terminus. We
propose that this could explain the late onset of the disease
with legal blindness occurring after a mean age of 60 years.
In comparison, the mean age of legal blindness for
mutations in the first 14 exons and in the 5’ region of
ORF15 was 45 years in RP patients [16].
Why do some ORF15 mutations affect rods, and others
cause predominantly cone involvement? [27] Several
speculations can be made. Mutant mice with different
mutations exhibit mis-localization of rod and/or cone (rhod)
opsins. Which opsin is mis-localized most depends on the
type of mutation [28]. In humans, there is also a genotype-
phenotype relation: certain mutations predispose to rod cell
loss and others affect mostly cones. The RPGR protein is
expressed in the basal body of the connecting cilium of
both rod and cone photoreceptors. The connecting cilium
serves as a conduit for bidirectional transport of protein
complexes, and is important for the outer segment disc
morphogenesis and renewal [29]. For execution of its
transport function, the RPGR protein interacts with other
ciliary proteins like RPGRIP1, CEP290, NPHP5, and
NPHP6 [30]. These protein interactions are known to differ
among rods and cones, and certain mutations may have
more effect on cone interactions than those of rods and
vice versa.
The duplication of family 1 (c.3317dup) had been
reported earlier by Demirci et al., who observed this
mutation in an individual with CRD [11]. In our family,
the rods were spared in virtually all patients. Variation in
phenotype in patients with identical mutations may be due
to post-translational effects by modifying genes or environ-
mental factors [31]. However, the homogeneity of the
phenotype in family 1 signifies that these effects are
probably small.
The female carriers in both our families did not have any
ocular involvement. In many reports of RP families with
ORF15 mutations, carriers have mild or even severe
ophthalmologic abnormalities, ranging from pigmentary
changes in the periphery to severe visual loss [5, 32, 33].
Mutations causing a widespread photoreceptor decay may
be more difficult to compensate for the non-mutated X-
allele than mutations causing a more restricted dysfunction
of the photoreceptors [5].
A large proportion of the CD patients in our families had
high myopia of more than 6 D (17/25;73%). Photoreceptor
disorders commonly have high myopia, independent of
genetic etiology or inheritance mode [34–36]. The reasons
for this phenomenon remain unclear. One explanation may
be that scleral growth is stimulated by signals from
dysfunctional photoreceptors; another is that high myopia
and primary photoreceptor disorders are part of the same
syndrome.
In conclusion, this is a comprehensive clinical report of
two families with pure cone involvement due to RPGR
ORF15 mutations. Our survival analyses can be useful to
counsel such patients. This report adds to the growing
evidence that RPGR, an established gene for rod cell loss,
can be restricted to cone cell loss.
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